<DOC>
	<DOCNO>NCT03093636</DOCNO>
	<brief_summary>The purpose study reduce frequency hypoglycemia severe hypoglycemic event subject use insulin pen treat Type 1 Diabetes Mellitus ( T1DM ) . Hypoglycemia number one fear many individual family someone type 1 diabetes , fear often prevent optimal glycemic control . It expect protocol yield increase knowledge use decision support system help control glucose level .</brief_summary>
	<brief_title>Efficacy inControl Advice : A Decision Support System ( DSS ) Diabetes</brief_title>
	<detailed_description>This study 12-week parallel group multi-center randomize trial design compare CGM+DSS CGM alone . The DSS implement contains `` smart '' bolus advisor adjusts size correction insulin bolus base short term blood glucose prediction . It able complete function evaluate CGM value , insulin usage carbohydrate intake record . It also contain exercise advisor , bedtime advisor , hypoglycemia risk long-term tracker HbA1c . inControl-Advice , smart-phone base medical software platform , design provide advice user . It receive data insulin pen adjustment insulin delivery every 5 minute . The system provide series real-time alert on-demand advice , dose insulin ingestion carbohydrate , base data collect T1DM patient ( i.e . carbohydrate consumption , insulin inject , CGM ) inConrol Cloud analytics .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<criteria>1 . Willingness provide informed consent 2 . Clinical diagnosis , base investigator assessment , type 1 diabetes least one year use insulin least 1 year 3 . Using basal ( Lantus® [ insulin glargine ] , Levemir® [ insulin detemir ] , Tresiba® [ insulin degludec ] ) meal insulin ( NovoLog® [ insulin aspart ] , Humalog® [ insulin lispro ] Apidra® [ insulin glulisine ] ) Intensive Insulin Therapy include carbohydrate counting use predefined parameter glucose goal , carbohydrate ratio , insulin sensitivity factor least 6 month . . Acceptable basal insulin regimen include : i. Lantus® ( insulin glargine ) 100U/mL twice daily ii . Levemir® ( insulin detemir ) 100U/mL twice daily iii . Tresiba® ( insulin degludec ) 100U/mL daily 4 . Age ≥15.0 year old 5 . Willingness use study basal insulin ( Tresiba® [ insulin degludec ] ) meal insulin ( NovoLog® [ insulin aspart ] ) duration study . 6 . Willingness use home DSSoptimized carbohydrate count parameter meal dose enter information inControl APP ( CGM+DSS group ) . 7 . For female , currently know pregnant 8 . If female sexually active , must agree use highly effective form contraception prevent pregnancy participant study . A negative serum urine pregnancy test require premenopausal woman surgically sterile . Subjects become pregnant discontinue study . Also , subject study develop express intention become pregnant within timespan study discontinue . 9 . Ability access Internet provide data clinical team travel research center study equipment download . 10 . Ability 3G WiFi able use DSS smart bolus calculator advice give ( i.e . sleep , exercise ) . 11 . Demonstration proper mental status cognition study 12 . Investigator confidence subject successfully operate study device capable adhere protocol 13 . If noninsulin hyperglycemic therapy , stability therapy prior 3 month willingness alter therapy study duration . 1 . Medical need chronic acetaminophen 2 . Use medication discretion clinical protocol chair deem interfere trial . 3 . Current treatment seizure disorder . 4 . Coronary artery disease heart failure , unless write clearance receive cardiologist . 5 . Hemophilia bleed disorder 6 . A known medical condition , opinion investigator designee , would put participant study risk follow example : 1 . Inpatient psychiatric treatment past 6 month 2 . Presence known adrenal disorder 3 . Abnormal liver function test result ( Transaminase &gt; 3 time upper limit normal ) 4 . Abnormal renal function test result ( calculated GFR &lt; 60 mL/min/1.73m2 ) . 5 . Active gastroparesis require medical therapy 6 . Uncontrolled thyroid disease ( TSH undetectable &gt; 10 mlU/L ) . 7 . Abuse alcohol recreational drug 8 . Infectious process anticipate resolve prior study procedure ( e.g . meningitis , pneumonia , osteomyelitis , deep tissue infection ) . 9 . Uncontrolled arterial hypertension ( Resting diastolic blood pressure &gt; 100 mmHg and/or systolic blood pressure &gt; 180 mmHg ) . 10 . Uncontrolled microvascular complication current active proliferative diabetic retinopathy define proliferative retinopathy require treatment ( e.g . laser therapy VEGF inhibitor injection ) past 12 month . 7 . A recent injury body limb , muscular disorder , use medication , carcinogenic disease , significant medical disorder injury , medication disease judgment investigator affect completion protocol . 8 . Current use follow drug supplement : k. Regular acetaminophen user , willing suspend acetaminophen 24 hour entire length trial l. Oral steroid m. Any medication investigator believe contraindication subject 's participation 9 . Participation another pharmaceutical device trial time enrollment study</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>100 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Type 1 Diabetes Mellitus ( T1DM )</keyword>
	<keyword>Continuous Glucose Monitor ( CGM )</keyword>
	<keyword>Multiple Daily Injections ( MDI )</keyword>
	<keyword>Insulin Pen</keyword>
	<keyword>inControl Advice</keyword>
	<keyword>Decision Support System ( DSS )</keyword>
</DOC>